Advertisement
Advertisement
RNA
Atrium Therapeutics, Inc. Common Stock
8.23
USDSponsored
-0.15
-1.79%
Nov 10, 15:59 UTC -5
Closed
After-Market
8.27
+0.04
+0.43%
Atrium Therapeutics, Inc. Common Stock (RNA) Earnings
RNA Earnings Reports
Positive Surprise Ratio
RNA beat 14 of 24 last estimates.
58%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Atrium Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 13, 2026, RNA reported earnings of -1.18 USD per share (EPS) for Q2 26, beating the estimate of -1.43 USD, resulting in a 17.58% surprise. Revenue reached 3.00 million, compared to an expected 673.34 thousand, with a 346.14% difference. The market reacted with a +4.14% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ocular Therapeutix, Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.42
Surprise
-13.54%
Harrow, Inc. Common Stock
Report Date
Nov 09, 2026 For Q3 26
Estimate
$0.22
Actual
$0.12
Surprise
-45.92%
SIGA Technologies Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-Actual
-$0.04
Surprise
-
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Tonix Pharmaceuticals Holding Corp.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$2.40
Actual
-$2.89
Surprise
-20.23%
Cumberland Pharmaceuticals Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-Actual
-$0.07
Surprise
-
PMV Pharmaceuticals, Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.23
Actual
-$1.81
Surprise
-46.07%
Heron Therapeutics, Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-9.09%
FAQ
What were Atrium Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Atrium Therapeutics, Inc. Common Stock reported EPS of -$1.18, beating estimates by 17.58%, and revenue of $3.00M, 346.14% above expectations.
How did the market react to Atrium Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 4.14%, changed from $12.33 before the earnings release to $12.84 the day after.
When is Atrium Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Atrium Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Atrium Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.